Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy.

Rawal, Shalin; Sharma, Kamal; Shah, Aditya; Bavishi, Shriya; Christian, Cleris; Bhatt, Parjanya; Konat, Ashwati

Rawal, Shalin; Sharma, Kamal; Shah, Aditya; Bavishi, Shriya; Christian, Cleris; Bhatt, Parjanya; Konat, Ashwati.

Afiliação

Rawal S; Intern MBBS, B. J. Medical College and Civil Hospital, Ahmedabad, India.
Sharma K; Department of Cardiology, SAL Hospital, Ahmedabad, India.
Shah A; Intern MBBS, B. J. Medical College and Civil Hospital, Ahmedabad, India.
Bavishi S; Intern MBBS, B. J. Medical College and Civil Hospital, Ahmedabad, India.
Christian C; Intern MBBS, B. J. Medical College and Civil Hospital, Ahmedabad, India.
Bhatt P; Intern MBBS, B. J. Medical College and Civil Hospital, Ahmedabad, India.
Konat A; Department of Zoology, Biomedical Technology, and Human Genetics, Gujarat University, Ahmedabad, India.

Front Cardiovasc Med ; 9: 916705, 2022.

Article em En | MEDLINE | ID: mdl-35811704

Palavras-chave

Quality-Adjusted Life-Years (QALY); cost-effectiveness; dual pathway inhibitor; incremental cost-effectiveness ratio (ICER); rivaroxaban

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google